Innoviva (INVA) Non-Current Deferred Tax Liability (2022 - 2026)
Innoviva posted quarterly Non-Current Deferred Tax Liability of $72.8 million for Q1 2026, up 129.08% on a QoQ basis from $31.8 million in Q4 2025.
Innoviva (INVA) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $72.8 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deferred Tax Liability changed N/A year-over-year to $72.8 million; the trailing twelve-month figure through Mar 2026 stood at $72.8 million (changed N/A YoY), and the FY2025 full-year result was $31.8 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $72.8 million, up from $31.8 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $72.8 million in Q1 2026 and bottomed at $360000.0 in Q3 2022.
- The 5-year median for Non-Current Deferred Tax Liability is $5.4 million (2023), against an average of $17.2 million.
- The widest annual swing landed in 2023, when Non-Current Deferred Tax Liability slumped 90.24%; it then retreated 29.4% in 2024.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $5.8 million in 2022, then plunged by 90.24% to $563000.0 in 2023, then surged by 576.2% to $3.8 million in 2024, then jumped by 735.12% to $31.8 million in 2025, then jumped by 129.08% to $72.8 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $72.8 million (Q1 2026), $31.8 million (Q4 2025), and $3.8 million (Q1 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72.83 Mn |
| Mar 31, 2026 | 72.83 Mn |
| Dec 31, 2025 | 31.79 Mn |
| Dec 31, 2025 | 31.79 Mn |
| Mar 31, 2024 | 3.81 Mn |
| Mar 31, 2024 | 3.81 Mn |
| Dec 31, 2023 | 563,000.00 |
| Dec 31, 2023 | 563,000.00 |
| Mar 31, 2023 | 5.39 Mn |
| Mar 31, 2023 | 5.39 Mn |
| Dec 31, 2022 | 5.77 Mn |
| Dec 31, 2022 | 5.77 Mn |
| Sep 30, 2022 | 360,000.00 |
| Sep 30, 2022 | 360,000.00 |